U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday.The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.Check This Out: How To Earn $500 A Month From Lamb Weston Stock Ahead Of Q1 EarningsLeading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, energy stocks fell by 1.9%.Top HeadlineCarnival (NYSE: CCL) reported better-than-expect ...

PresentationAt this time, I'd like to turn the call over to Greg Duncan, Chief Executive Officer for Dogwood Therapeutics. Please proceed, Mr. Duncan.Good morning, and welcome to today's Dogwood Therapeutics, Inc. Investor Call. [Operator Instructions] And please be advised that today's call is being recorded at the company's request.Greg DuncanChairman & CEO Thank you. Good morning all, and thank you for joining today's exciting investor call for Dogwood Therapeutics. I'm pleased to be joined by our Chief ...

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its share ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro.On Monday, the company announced that its CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect (PCED) did not meet the primary endpoint of complete healing of PCED as measured by corneal fluorescein stainin ...

An unheralded New York–listed biotech is chasing one of neurology’s biggest goals: a pill that not only tamps down the inflammatory flares of multiple sclerosis but also directly protects the brain from the slow, steady damage that leaves many patients disabled. Immunic Inc (NASDAQ:IMUX) is developing vidofludimus calcium, an oral medicine it says is “first-in-class” because it combines two mechanisms: one to reduce relapses and magnetic resonance imaging (MRI) lesions, and another aimed at shielding neuron ...

J Studios/DigitalVision via Getty Images Dear Baron International Growth Fund Shareholder: Baron International Growth Fund® (the Fund) gained 16.91% (Institutional Shares) during the second quarter of 2025, while its primary benchmark, the MSCI ACWI ex USA Index (the Benchmark), appreciated 12.03%. The MSCI ACWI ex USA IMI Growth Index (the Proxy Benchmark) gained 14.41% for the quarter. The Fund solidly outperformed both the Benchmark and the Proxy Benchmark during a strong quarter for global equities ...

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s ataxia (FA).The OL study is evaluating the safety and tolerability, pharmacokinetics (PK), and FXN levels in skin and buccal cells, along with exploratory pharmacodynamic (PD) markers (lipid profiles) and cli ...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mltx. What is this all about? Shares of MoonLake Immunotherapeutics fell more than 85% in pre-market trading on September 29 after the com ...

转自：新华财经 以"汇新智・促转化・共筑国际健康创新生态"为主题的第七届健康中国・思南对话9月28日在沪举办，来自政府部门、科研机构、医疗机构、产业主体及投 资领域的代表汇聚一堂，聚焦生物医药创新转化与国际合作重点方向，共同研究谋划产业发展新路径。 上海市黄浦区委书记杲云在致辞中表示，将强化广慈-思南园区的平台功能，构建以数字科技和生命健康为核心的"2+1"现代产业体系。他特别提及世博浦西 片区"中央科创区"规划，称该区域以数字科技、生命健康为核心产业方向，将打造全球创新要素融汇之地，诚邀企业英才扎根发展。 中国工程院院士、瑞金医院院长宁光介绍，瑞金医院联合黄浦区共建广慈—思南园区，推动多领域跨界融合，国产首台套质子治疗装置、开源病理大模型等 标志性成果已成功落地。未来，医院将深化"医产学研企"协同，主动融入黄浦中央科创区建设。 为推动理念落地，本次会议举行了八大发布与签约环节，涵盖生态构建、人才保障、技术创新等关键领域。黄浦区与瑞金医院共同启动了"广慈思南（中港 汇）医学转化创新生态发布仪式"；"园区人才企业年金计划"启航，成为了上海市同类政策在黄浦区及国家级园区的首次落地，彰显了引才留才决心；"瑞金 医学 ...